Therapeutic effect of amtiriptyline combined with opioids for moderate to severe cancer pain patients with depression

Abstract

Abstract:

AIM: To investigate the effect and safety of amitriptyline combined with opioid for moderate to severe cancer pain patients with depression. METHODS: Forty-two patients with moderate to severe cancer pain and depression were randomly divided into two groups. The control group was given strong opioids (n=21), the treatment group was given opioids combined with amitriptyline (n=21). The digital classification method (NRS), depression self rating scale (SDS) and Hamilton depression scale (HAMD 17), quality of life questionnaire (SF-36) were used to assess the clinical effect of pain, depression and quality of life. In addition, the opioids dose and adverse drug reactions were recorded. RESULTS: Pain was significantly alleviated in each group (P<0.01) after two or four weeks, and the NRS of the treatment group was better than that of the control group after two or four weeks (P<0.05); depression was relieved in each group (P<0.01), and the depression score of the treatment group was better than that of the control group (P<0.05); after the treatment, the quality of life had improved to a certain extent in both groups, and the emotional function, energy, mental health, social functioning and body pain in the treatment group were better than those of the control group (P<0.05); the average daily dosage of opioids for treatment group was significantly lower than that of the control group after four weeks (P<0.01); the total incidence of adverse of the treatment group was slight higher than that of the control gtoup (P>0.05), but the dizziness, sleepiness and urinary retention were obviously more than those of the control group (P<0.05). CONCLUSION: Amitriptyline combined with opioids can effectively control severe cancer pain, relieve depressive symptoms, and improve the quality of life for cancer pain patients, which is referential for clinical application.

Key words: amitriptyline, opioids, cancer pain, depression, quality of life

CLC Number:

R749

XU Xiangwei, CHEN Yanqiao, ZHU Peizhen. Therapeutic effect of amtiriptyline combined with opioids for moderate to severe cancer pain patients with depression[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1145-1151.

References

［1］Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 ［J］. CA: A Cancer Journal for Clinicians, 2016, 66(2):115-132.
［2］闫晓倩, 赵君慧, 王淼舟. 癌痛规范化诊治的研究现状及影响因素分析［J］. 中国现代医药杂志, 2015, 17(10): 104-106.
［3］李小梅, 肖文华, 焦顺昌,等. 一项癌痛患者焦虑抑郁的回顾性队列研究［J］. 中国疼痛医学杂志, 2016, 22(5):354-359.
［4］中华人民共和国卫生部(卫办医政发［2011］161号). 癌症疼痛诊疗规范(2011年版)［J］.临床肿瘤学杂志, 2012, 17(2): 153-158.
［5］严敏. 癌痛规范化治疗及2010年《NCCN成人癌痛临床实践指南》(中国版)解读［J］.现代实用医学, 2012, 24(2):127-129.
［6］方翠娴. SAS或SDS评估量表在晚期癌症患者中的应用［J］.中国现代药物应用, 2015(15):237-239.
［7］Wagner S, Helmreich I, Lieb K, et al. Standardized rater training for the Hamilton Depression Rating Scale (HAMD17) and the Inventory of Depressive Symptoms (IDS(C30))［J］. Psychopathology, 2010, 44(1):68-70.
［8］胡彩平, 林毅, 李秋萍. SF-36量表与QLQ-C30量表在老年癌症病人生活质量评估中的应用及其相关性研究［J］. 护理研究, 2015(8):2968-2972.
［9］Eskelinen M, Korhonen R, Selander T, et al. Agreement between hopelessness/helplessness and montgomery-asberg depression rating scale in healthy individuals and in patients with benign breast disease and breast cancer: a prospective case-control study in Finland.［J］. Anticancer Research, 2015, 35(4):2215-2221.
［10］陈敬贤, 沈小珩, 吕玲玲,等. 血府逐瘀汤加味治疗肺癌/乳腺癌伴情绪障碍［J］.长春中医药大学学报, 2016, 32(5):994-997.
［11］王苗苗, 吴密璐. 恶性肿瘤抑郁症的临床研究进展［J］. 现代肿瘤医学, 2016, 24(8):1315-1317.
［12］Muzzatti B, Mella S, Bomben F, et al. Intensity and prevalence of depressive states in cancer inpatients: a large sample descriptive study［J］. European J Cancer Care(Engl), 2016,6(10):1-5.
［13］Larson SL, Clark MR, Eaton WW. Depressive disorder as a long-term antecedent risk factor for incident back pain: a 13-year follow-up study from the Baltimore Epidemiological Catchment Area sample［J］. Psychol Med， 2004, 34(2):211-219.
［14］桂冰, 陈永和. 癌症疼痛心理社会干预治疗的研究进展［J］.医学与哲学, 2014(10):12-15.
［15］丁亚文, 冯刚, 张丽娟,等. 盐酸文拉法辛胶囊联合羟考酮缓释片治疗中重度癌痛的临床研究［J］. 华中科技大学学报(医学版), 2012, 41(4):485-489.
［16］柯莹姣, 张建华.单用吗啡与联合用药治疗晚期癌痛的疗效观察［J］. 中外医学研究, 2015，13(11):1-3.
［17］王剑钢.盐酸羟考酮缓释片联合阿米替林对重度癌症疼痛伴抑郁患者疗效分析［J］. 温州医科大学学报, 2016, 46(3):215-217.
［18］陈卓明. 40例晚期胰腺癌疼痛治疗疗效观察［J］. 医学综述, 2013, 19(24):4570-4572.
［19］彭鹏, 郑莹, 王杰军,等. 癌痛患者的生活质量及其影响因素研究［J］.中国肿瘤, 2009, 18(4):273-277.
［20］杨萍, 孙丽秋, 路潜,等. 癌痛病人生活质量状况及其相关因素研究［J］. 中国护理管理, 2012, 12(2):25-28.
［21］冉凤鸣, 臧爱华. 重视阿片类镇痛药物的不良反应［J］. 药品评价, 2012, 9(3):42-44.
［22］韩金凤, 刁殿军, 刘春香,等. 自拟方治疗癌痛患者应用阿片类药物所致便秘［J］. 长春中医药大学学报, 2015, 31(3):572-575.

[1]	ZHANG Taotao, SU Wenxiu, TIAN Limin. Research progress on the relationship between subclinical hypothyroidism and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 954-960.
[2]	NI Yuanbo, ZHANG Xin, LI Yi, LIU Cunming. Anesthetics, analgesics and cognitive function [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1365-1374.
[3]	HE Teng, XU Xiangyang, XU Xiangqing, LIU Cunming, YANG Chun. Ketamine for depression treatment: past, present, and future [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1125-1132.
[4]	WANG Yeqing, WANG Yuhong, LIU Jian, ZHAO Hongqing, ZOU Manshu. Research progress of relevance between cholecystokinin and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 672-679.
[5]	CHEN Ying, YUAN Yonggui. Research progress in the treatment of depression with monome of Chinese herb, drug pairs, compound prescriptions and Chinese patent drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 586-593.
[6]	ZHOU Haihui, ZHANG Haixia, GE Weihong. Analysis of the role of clinical pharmacist in the establishment of standardized cancer pain management ward [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1038-1042.
[7]	YANG Shitao, ZHU Yihong, TANG Wenxin. Effects of aripiprazole combined with duloxetine on the treatment effect and VEGF level in patients with refractory depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 937-942.
[8]	GE Wei, SHENG Wenyan, XU Qibing, LI Qiushi, SU Lingya, WU Shuangqing. Effects of SSRI antidepressant sertraline on ocular surface function in patients with postpartum depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 440-446.
[9]	FENG Rui, ZHANG Jiali, HE Mingchao, LI Yue, ZHANG Yan. Pharmacological targets and clinical application of traditional Chinese medicine and active components in the prevention and treatment for depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 467-474.
[10]	WANG Sijie，ZHANG Jun，LI Qian，HUANG Hua，WANG Jingjing，ZHOU Qiong，YAO Qin. Research progress on the safety and effectiveness of escitalopram in the treatment of pregnant women with depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1070-1074.
[11]	ZHOU Yancan. Effects of agomelatine on depressive disorder and brain-derived neurotrophic factor ZHOU Yancan [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 699-703.
[12]	HU Defeng, WANG Yihu, LONG Xiaoyu, WANG Guangshui. Intervention effect of modified Ganmaidazao Tang combined with cognitive behavioral intervention on ultra-high risk for developing psychosis and the effects on cognitive function, quality of life and serum levels of 5-HT, MT and TSH [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 546-553.
[13]	CHEN Lianzhou, LI Songhua, PU Ben. Effects of aripiprazole combined with escitalopram oxalate on DA, 5-HT and cortisol in patients with severe depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 446-450.
[14]	WANG Ente, ZHANG Xiaodan, ZHOU Shuang, ZHAO Xia, ZHOU Ying, CUI Yimin. Effects of genetic polymorphisms on metabolic kinetics, pharmacodynamics and adverse reactions of amitriptyline [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 235-240.
[15]	CAI Dandan, GUI Donghui, ZHANG Jianbing, ZHOU Wenhua. Clinical efficacy of low dose risperidone combined with trazodone in the treatment of heroin addicts during detoxification [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 94-98.